Replies to post #115 on Conatus Pharmaceuticals Inc. (CNAT)

[truetrue]

I'm confused now. Where did "Master" post 56 days ?? Don't see it anywhere...I read the second half of 2014 in the company PR. I can wait 3 or 4 months to see if it's thumbs up or down.

http://ih.advfn.com/p.php?pid=nmona&article=62188617

NAFLD/NASH Update

Conatus initiated a Phase 2 trial of emricasan in patients with NAFLD, including patients with NASH, in March 2014. The trial is intended to confirm the appropriate dosing in this patient population for potential future studies, to expand emricasan's safety database, and to evaluate changes in relevant biomarkers of liver damage.

"There is not yet an established regulatory approval pathway in the NASH population, but we intend to be ready to move forward once appropriate Phase 3 endpoints are confirmed," said Dr. Mento.

Top-line results from the Phase 2 clinical trial are expected in the second half of 2014.